Zomedica Pharmaceuticals Corp - Asset Resilience Ratio
Zomedica Pharmaceuticals Corp (ZOM) has an Asset Resilience Ratio of 38.30% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Zomedica Pharmaceuticals Corp's Asset Resilience Ratio has changed over time. Check Zomedica Pharmaceuticals Corp PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Zomedica Pharmaceuticals Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Zomedica Pharmaceuticals Corp market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $54.77 Million | 38.3% |
| Total Liquid Assets | $54.77 Million | 38.30% |
Asset Resilience Insights
- Very High Liquidity: Zomedica Pharmaceuticals Corp maintains exceptional liquid asset reserves at 38.30% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Zomedica Pharmaceuticals Corp Industry Peers by Asset Resilience Ratio
Compare Zomedica Pharmaceuticals Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Pulsenmore Ltd. Ordinary Shares
NASDAQ:PLSM |
Medical Devices | 46.67% |
|
Medartis Holding AG
SW:MED |
Medical Devices | 0.00% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932 |
Medical Devices | 34.47% |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO |
Medical Devices | 30.97% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Respiri Ltd
AU:RSH |
Medical Devices | 0.46% |
Annual Asset Resilience Ratio for Zomedica Pharmaceuticals Corp (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Zomedica Pharmaceuticals Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 31.02% | $64.33 Million | $207.36 Million | +0.40pp |
| 2023-12-31 | 30.63% | $77.55 Million | $253.20 Million | -10.54pp |
| 2022-12-31 | 41.16% | $115.09 Million | $279.61 Million | -28.37pp |
| 2021-12-31 | 69.53% | $194.95 Million | $280.40 Million | -24.20pp |
| 2020-12-31 | 93.72% | $61.99 Million | $66.14 Million | +56.82pp |
| 2019-12-31 | 36.91% | $1.54 Million | $4.18 Million | -16.09pp |
| 2018-12-31 | 53.00% | $3.20 Million | $6.03 Million | -24.04pp |
| 2017-12-31 | 77.04% | $4.02 Million | $5.22 Million | +10.86pp |
| 2016-12-31 | 66.18% | $3.23 Million | $4.88 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $3.86 Million | -- |
About Zomedica Pharmaceuticals Corp
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital sign… Read more